The Quest for Enhanced Mucosal Immunity

The current landscape of COVID-19 vaccination has demonstrated remarkable success in preventing severe disease and death globally. However, traditional intramuscular injections primarily stimulate systemic immunity while providing relatively limited protection at the respiratory mucosal surfaces. Consequently, researchers have focused on developing the intranasal NDV-HXP-S vaccine to address this critical gap in immune defense and potentially reduce transmission. This innovative approach utilizes a viral vector to deliver a stabilized spike protein directly to the nasal passages. By targeting the primary site of viral entry, this vaccine candidate aims to neutralize the virus before it can establish a robust infection. Furthermore, the development of such mucosal boosters represents a significant shift toward next-generation immunization strategies for respiratory pathogens. The recent Phase 1 trial conducted in New York City provides early but encouraging evidence regarding the safety and potential efficacy of this delivery method. Therefore, understanding the mechanistic and clinical nuances of this platform is essential for improving future pandemic preparedness and public health outcomes.

Understanding the Intranasal NDV-HXP-S Vaccine Platform

Specifically, the NDV-HXP-S candidate utilizes the Newcastle Disease Virus (NDV) as a delivery vector for the SARS-CoV-2 spike protein. NDV is an avian paramyxovirus that does not cause disease in humans, which means that most individuals lack pre-existing immunity to the vector. In addition, the vaccine incorporates the "Hexapro" spike protein, which features six proline substitutions to stabilize the antigen in its prefusion conformation. This stabilization is crucial because it enhances the expression of the protein and improves the resulting immune response. Moreover, the vaccine is designed to be produced using egg-based manufacturing technology, which is the same infrastructure currently used for global influenza vaccine production. This choice is significant because it allows for scalable and cost-effective manufacturing, particularly in low- and middle-income countries. Consequently, the NDV-HXP-S platform offers a practical solution to the challenges of vaccine equity and distribution. Nevertheless, the primary focus of early-stage trials remains the rigorous assessment of safety and dose-dependent immunogenicity in human populations.

Clinical Methodology and Participant Demographics

Between February 2022 and April 2024, clinical investigators enrolled thirty-five healthy adults at a single research site in New York City. These participants had previously received authorized COVID-19 vaccines but had no history of prior SARS-CoV-2 infection. The researchers randomized the subjects to receive either a low or high dose of the live recombinant vaccine. Additionally, the study evaluated three different administration routes: intranasal (IN), intramuscular (IM), or a simultaneous combination of both (IN+IM). A placebo group was also included to provide a baseline for safety and immunogenicity comparisons. While the sample size was intentionally small for this Phase 1 evaluation, the trial design allowed for a detailed analysis of systemic and local immune responses. Specifically, the team monitored the participants for safety for a full year and collected serum and saliva samples through day 84. Furthermore, exploratory analyses included the measurement of T-cell activity to gain a comprehensive understanding of the cellular immune profile. Thus, this trial represents a foundational step in characterizing the human response to the intranasal NDV-HXP-S vaccine.

Safety Profile and Regulatory Tolerability

The primary finding of this Phase 1 trial was that the vaccine demonstrated an acceptable safety profile across all tested doses and routes. Specifically, all 35 participants completed the study follow-up period without experiencing any serious adverse events. Most reported side effects were classified as Grade 1 or 2, which are typically mild and transient in nature. In contrast to some systemic vaccines, the intranasal administration did not result in unexpected local or systemic toxicity. Furthermore, the Data Safety Monitoring Board regularly reviewed the progress of the trial and found no reasons to halt the investigation. Notably, the tolerability of the vaccine in previously immunized adults suggests that it can be safely used as a heterologous booster. Consequently, these results support the continued clinical development of the NDV-based platform for various infectious disease targets. However, researchers emphasize that larger Phase 2 and Phase 3 trials are necessary to confirm these safety findings in more diverse populations. Nevertheless, the current data provides the necessary confidence to move forward with updated formulations and expanded study protocols.

Analyzing the Immunogenicity Outcomes

Regarding immunogenicity, the exploratory results indicated that the vaccine effectively maintained or boosted immune markers in the participants. While placebo recipients experienced a predictable waning of antibody titers over time, those who received the active vaccine showed stable or increased serum IgG levels. More importantly, the intranasal delivery route successfully elicited a modest rise in salivary secretory IgA (sIgA) levels. This mucosal response is particularly significant because sIgA plays a vital role in preventing the virus from adhering to the respiratory lining. Furthermore, participants who began the study with low baseline cellular immunity showed a measurable increase in CD4+ T-cell activity by day 28. In addition, the neutralizing activity against the virus was maintained, suggesting that the vaccine provides broad systemic protection. However, the researchers noted that the mucosal responses were somewhat variable among individuals, which may be influenced by baseline immunity or the specific dose administered. Therefore, future studies will likely focus on optimizing the delivery method to ensure consistent mucosal protection across all recipients.

Future Directions for Next-Generation Vaccines

In conclusion, the successful completion of this Phase 1 study marks a pivotal moment for the development of mucosal COVID-19 vaccines. The data suggests that the intranasal NDV-HXP-S vaccine is not only safe but also capable of stimulating both systemic and local immune pathways. Specifically, the ability to utilize existing egg-based manufacturing facilities could facilitate the rapid production of updated vaccines as new variants emerge. Furthermore, the transition toward intranasal boosters could play a major role in reducing the global burden of respiratory infections by limiting viral shedding. Consequently, investigators are now preparing for larger, controlled studies to evaluate the efficacy of updated vaccine versions that target current variants of concern. These future trials will be essential for determining whether the observed immunogenicity translates into a significant reduction in infection rates. Notably, the integration of mucosal immunity into the broader vaccination strategy remains a top priority for global health organizations. Therefore, the findings from this New York City trial provide a promising roadmap for the next phase of the global fight against SARS-CoV-2.

Frequently Asked Questions

How does the NDV-HXP-S vaccine differ from current mRNA vaccines?

Unlike mRNA vaccines that deliver genetic instructions via lipid nanoparticles, the NDV-HXP-S vaccine uses a live recombinant Newcastle Disease Virus as a vector. This avian virus is harmless to humans but effectively displays the stabilized spike protein to the immune system. Specifically, the intranasal route allows the vaccine to stimulate local mucosal immunity in the respiratory tract, a feature that traditional intramuscular mRNA injections do not prioritize as effectively.

What were the primary safety findings of the Phase 1 trial?

The Phase 1 trial demonstrated that the vaccine was safe and well-tolerated in all 35 participants. Specifically, there were no serious adverse events reported throughout the year-long monitoring period. Most participants experienced only mild Grade 1 or 2 side effects, which are typical for viral vector vaccines. These results indicate that the vaccine can be safely administered to adults who have already received other types of COVID-19 vaccinations.

Why is mucosal immunity important for preventing COVID-19 transmission?

Mucosal immunity is essential because it provides a first line of defense at the point of viral entry. By stimulating secretory IgA antibodies in the nose and throat, the vaccine can neutralize SARS-CoV-2 before it infects the body's cells. Furthermore, this local immune response may reduce the amount of virus an infected person sheds, thereby potentially lowering the risk of transmitting the virus to others in the community.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Liu STH et al. Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults. Vaccine. 2026 Jun 30. doi: undefined. PMID: 42378814.

ClinicalTrials.gov. A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study. NCT05181709.

Sun W, et al. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat Commun. 2021;12(1):6197.

Mount Sinai Health System. Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine. July 2023.